Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2025; 31(3): 95207
Published online Jan 21, 2025. doi: 10.3748/wjg.v31.i3.95207
Published online Jan 21, 2025. doi: 10.3748/wjg.v31.i3.95207
In silico analysis of lncRNA-miRNA-mRNA signatures related to Sorafenib effectiveness in liver cancer cells
Patricia de la Cruz-Ojeda, Functional Genomics of Solid Tumors Laboratory, Centre de Recher
Patricia de la Cruz-Ojeda, Ester Parras-Martínez, Raquel Rey-Pérez, Jordi Muntané, Department of Oncology Surgery, Cell Therapy and Organ Transplantation, Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, Seville 41013, Spain
Patricia de la Cruz-Ojeda, Jordi Muntané, Biomedical Research Center for Hepatic and Digestive Diseases, CIBERehd, Madrid 28029, Spain
Jordi Muntané, Department of Medical Physiology and Biophysics, University of Seville, Seville 41009, Spain
Author contributions: de la Cruz-Ojeda P performed the research, contributed to the implementation of analytical tools and edited the manuscript; Parras-Martínez E and Rey-Pérez R analyzed data; Muntané J designed the research, wrote the paper, and obtained funding. All authors have read and approved the final manuscript.
Supported by Instituto de Salud Carlos III (ISCiii), No. PI19/01266 and No. PI22/00857; Consejería de Salud y Familias (Junta de Andalucía), No. PI-0216-2020 and No. PIP-0215-2020; Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd) founded by the ISCIII and co-financed by European Regional Development Fund “A way to achieve Europe” ERDF.
Institutional review board statement: This study is based on the use of the HepG2 and SNU449 cell lines. The study did not require an Institutional review board.
Institutional animal care and use committee statement: This study is based on the use of HepG2 and SNU449 cell lines. The study did not require an Institutional Animal Care and Use Committee approval form.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Data will be freely available according to the requirement of the WJG as an open-access article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jordi Muntané, PhD, Department of Oncology Surgery, Cell Therapy and Organ Transplantation, Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, Avn. Manuel Siurot S/N, Seville 41013, Spain. jmuntane-ibis@us.es
Received: April 4, 2024
Revised: August 30, 2024
Accepted: September 12, 2024
Published online: January 21, 2025
Processing time: 259 Days and 21.6 Hours
Revised: August 30, 2024
Accepted: September 12, 2024
Published online: January 21, 2025
Processing time: 259 Days and 21.6 Hours
Core Tip
Core Tip: In the current study, we investigated the differential lncRNA-miRNA-mRNA regulatory axes in HepG2 and SNU449 under Sorafenib treatment. The study identified lncRNA-miRNA regulatory axes leading to increased expression mRNA with positive (SMAD7, TIRARP, TFAP4, FAXDC2 and ADRB2) and negative (VEGFA) therapeutic effects in HepG2 and SNU449 under Sorafenib treatment.